Summary
Amgen Inc. announced on November 18, 2004, the successful issuance of $2 billion in senior notes. This debt offering consists of $1 billion in 4.00% Senior Notes due 2009 and $1 billion in 4.85% Senior Notes due 2014. The net proceeds from this offering, estimated at approximately $1.99 billion, are primarily earmarked for the company's stock repurchase program and general corporate purposes, including capital expenditures and working capital. This significant debt financing demonstrates Amgen's strategy to fund shareholder returns and support ongoing business operations. Investors should note the maturity dates and interest rates associated with these notes, as well as the company's right to redeem them under specific conditions. The offering was conducted under an exemption from registration under the Securities Act of 1933, with a registration rights agreement in place to ensure future registration of the securities or compensation to holders.
Key Highlights
- 1Amgen issued $2 billion in senior notes: $1 billion of 4.00% Senior Notes due 2009 and $1 billion of 4.85% Senior Notes due 2014.
- 2Net proceeds from the offering are approximately $1.99 billion.
- 3Proceeds are primarily intended for the company's stock repurchase program.
- 4Funds will also be used for general corporate purposes, including capital expenditures and working capital.
- 5The notes were offered and sold under exemptions from registration under the Securities Act of 1933.
- 6A Registration Rights Agreement ensures Amgen will register the securities or pay additional amounts to holders if not registered within a specified time.
- 7Amgen retains the right to redeem the notes at any time, subject to a make-whole provision.